Renerve Limited Stock: price and insider trades · Australia

Renerve Limited, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to ASX. Between 28 October 2025 and 28 October 2026, 6 insiders published 8 filings.

Only purchases show up on the open market, 5 purchases in all worth €21k, filed by 3 insiders. The totals do not cover 3 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 3 senior executives. Biggest ticket of the year: €15k, bought by Julian John Chick and made public on 3 August 2026.

The clock since the last published purchase (6 October 2026) now reads 33 days. Publication is fast: at least half of the trades appear on ASX on the same day. This delay matters because a trade only becomes useful information once it is public.

Across the 1,603 companies tracked on its exchange, the median is 5 filings; at 8 filings, this issuer sits above that mark. Looking back to 2026, when coverage begins, insiders filed 5 purchases and no sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. This summary is built from ASX disclosures alone and does not predict where the share price will go.